Long-chain polyunsaturated fatty acid supplementation in preterm infants

Area of Science:

• Neonatal Nutrition
• Developmental Pediatrics
• Evidence-Based Medicine

Background:

• Preterm infants may have insufficient endogenous synthesis of longchain polyunsaturated fatty acids (LCPUFA).
• LCPUFA are crucial for the development of the brain and retina.
• The essentiality of LCPUFA for preterm infants remains a subject of debate.

Purpose of the Study:

• To evaluate the safety and efficacy of LCPUFA supplementation in preterm infant formula.
• To determine the impact of LCPUFA on neurodevelopment, visual acuity, and growth in preterm infants.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) identified through comprehensive database searches.
• Eligibility criteria focused on trials with clinical endpoints and LCPUFA-supplemented formula.
• Data extraction and quality assessment were performed by multiple authors.

Main Results:

• Most studies found no significant differences in visual acuity between supplemented and control groups.
• Meta-analyses showed no significant effect of LCPUFA supplementation on neurodevelopmental outcomes at 12 and 18 months post-term.
• Growth outcomes were mixed, with some studies reporting benefits at 2 months but no significant long-term effects on weight, length, or head circumference.

Conclusions:

• The reviewed trials included relatively mature and healthy preterm infants.
• Variations in study design, supplementation protocols, and control formulas limit definitive conclusions.
• Overall, no clear long-term benefits or harms were demonstrated for LCPUFA-supplemented formula in preterm infants.